Literature DB >> 29756174

Phenotypic detection of clinical isolates of Haemophilus influenzae with altered penicillin-binding protein 3.

A Aguirre-Quiñonero1,2, I C Pérez Del Molino3, C García de la Fuente3, M C Sanjuán3, J Agüero3,4, L Martínez-Martínez5,6,7.   

Abstract

The aims of this study were to determine the correlation of mutations in the ftsI gene (coding for PBP3) of Haemophilus influenzae with aminopenicillin resistance and to evaluate the 2017 European Committee for Antibiotic Susceptibility Testing (EUCAST) guidelines for clinical categorization of ampicillin, amoxicillin, and amoxicillin-clavulanate for strains with mutated PBP3 conferring resistance (rPBP3). A panel of 91 H. influenzae isolates was genetically characterized by sequencing of the fstI gene. For all the studied isolates, a screening with benzylpenicillin 1U (BP1) was carried out and minimum inhibitory concentrations (MICs) of ampicillin, amoxicillin, and amoxicillin-clavulanate were tested and interpreted according to EUCAST recommendations. ftsI sequence analysis revealed a total of 14 different amino acid substitutions in PBP3. The substitution patterns most commonly observed were [D350N, M377I, A502V, N526K] among the bla-positive rPBP3 strains (37.5%) and [D350N, A502T, N526K] among the bla-negative rPBP3 strains (24.5%). Screening with BP1 was able to correctly categorize 100% of the bla-negative sPBP3 strains, 100% of the bla-positive strains, and 92% of the bla-negative rPBP3 ones. Only 29% of the bla-negative rPBP3 strains evaluated displayed ampicillin MICs above the current EUCAST resistant breakpoint defined at 1 μg/ml. The PBP3 substitution patterns of the strains evaluated are similar to the ones observed in previous Spanish and European studies. Although the screening with BP1 proved to be adequate in the detection of bla-negative rPBP3 strains, these cannot be reliably identified by current 2018 EUCAST breakpoints for ampicillin.

Entities:  

Keywords:  EUCAST; Haemophilus influenzae; ftsI; rPBP3; β-lactam resistance

Mesh:

Substances:

Year:  2018        PMID: 29756174     DOI: 10.1007/s10096-018-3273-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae.

Authors:  Vlatka Matic; Bülent Bozdogan; Michael R Jacobs; Kimiko Ubukata; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

2.  Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin.

Authors:  Frank S Kaczmarek; Thomas D Gootz; Fadia Dib-Hajj; Wenchi Shang; Shawn Hallowell; Melissa Cronan
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae.

Authors:  W T M Jansen; A Verel; M Beitsma; J Verhoef; D Milatovic
Journal:  J Antimicrob Chemother       Date:  2006-08-04       Impact factor: 5.790

4.  Ampicillin-resistant Haemophilus influenzae isolates in Geneva: serotype, antimicrobial susceptibility, and β-lactam resistance mechanisms.

Authors:  A Cherkaoui; S M Diene; S Emonet; G Renzi; P Francois; J Schrenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-18       Impact factor: 3.267

5.  Haemophilus influenzae with Non-Beta-Lactamase-Mediated Beta-Lactam Resistance: Easy To Find but Hard To Categorize.

Authors:  Dagfinn Skaare; Astrid Lia; Anja Hannisdal; Yngvar Tveten; Erika Matuschek; Gunnar Kahlmeter; Bjørn-Erik Kristiansen
Journal:  J Clin Microbiol       Date:  2015-09-09       Impact factor: 5.948

6.  Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus influenzae beta-lactam resistance by using site-directed mutagenesis and gene recombinants.

Authors:  Yumi Osaki; Yumiko Sanbongi; Midori Ishikawa; Hiroshi Kataoka; Takahisa Suzuki; Kumiko Maeda; Takashi Ida
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Polymorphism in ftsI gene and {beta}-lactam susceptibility in Portuguese Haemophilus influenzae strains: clonal dissemination of beta-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid.

Authors:  Ana Raquel Barbosa; Maria Giufrè; Marina Cerquetti; Maria Paula Bajanca-Lavado
Journal:  J Antimicrob Chemother       Date:  2011-01-25       Impact factor: 5.790

8.  Disc diffusion susceptibility testing of Haemophilus influenzae by NCCLS methodology using low-strength ampicillin and co-amoxiclav discs.

Authors:  Pauliina Kärpänoja; Antti Nissinen; Pentti Huovinen; Hannu Sarkkinen
Journal:  J Antimicrob Chemother       Date:  2004-02-18       Impact factor: 5.790

9.  Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis.

Authors:  Keiko Hasegawa; Naoko Chiba; Reiko Kobayashi; Somay Y Murayama; Satoshi Iwata; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.

Authors:  Silvia García-Cobos; José Campos; Federico Román; Cristina Carrera; María Pérez-Vázquez; Belén Aracil; Jesús Oteo
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

View more
  1 in total

1.  Antimicrobial resistance among Haemophilus influenzae isolates responsible for lower respiratory tract infections in Poland, 2005-2019.

Authors:  Marlena Kiedrowska; Weronika Jasmina Foryś; Agnieszka Gołębiewska; Izabela Waśko; Patrycja Ronkiewicz; Alicja Kuch; Izabela Wróbel-Pawelczyk; Michał Wroczyński; Waleria Hryniewicz; Anna Skoczyńska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-18       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.